2020 operating cash burn is expected to be at the low end of the prior guidance range of $220-230M due to one-quarter delay (to 3Q20) in the US launch of Teoxane’s dermal fillers.
MYL’s decision whether to opt in for the Botox-biosimilar program is expected by the end of May.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.